Clinical development and analytics provider Phesi in partnership with Krystelis has launched a new service to recruit more diverse patients in clinical trials.
The collaboration between the two companies is a diversity, equity and inclusion (DEI) data service, the company said in a Sept. 6 press release. In addition to using Phesi’s Trial Accelerator platform, the offering includes Krystelis’ writing services.
The new offering aims to improve diversity in trials starting from the planning stage by minimizing protocol amendments that cost about $500,000 for each amendment. Additionally, it will meet global DEI rules from regulators including the FDA.
Financial details of the partnership weren’t disclosed.
“Without diverse patient cohorts that accurately reflect the patient population a drug is intended for, we cannot ensure that drugs will be fully safe or effective,” Phesi CEO Gen Li, Ph.D., said in the release.
Phesi rolled out its AI-based Trial Accelerator program last October, claiming it could save customers an average of $7 million per phase 3 trial.